8-K
false 0001796129 0001796129 2022-12-30 2022-12-30

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 30, 2022

 

 

Vincerx Pharma, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39244   83-3197402

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

260 Sheridan Avenue, Suite 400

Palo Alto, California

  94306
(Address of principal executive offices)   (Zip Code)

(650) 800-6676

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share   VINC   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 

 


Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective December 31, 2022, Dr. Andrew I. McDonald and Christopher P. Lowe resigned as members of the board of directors (the “Board”) of Vincerx Pharma, Inc. (the “Company”). Dr. McDonald had served as a member of the Board since the initial public offering of LifeSci Acquisition Corp. in March 2020, and Mr. Lowe had served as a member of the Board and as chair of the Audit Committee of the Board since the Business Combination. As stated in their resignation letters received on December 30, 2022, copies of which are attached as Exhibits 17.1 and 17.2, Dr. McDonald and Mr. Lowe resigned as a result of different views regarding Company strategy. There was no disagreement with the Company’s auditors or financial statements.

 

Item 9.01

Financial Statements and Exhibits.

 

(d)    Exhibits.
17.1    Letter from Dr. McDonald.
17.2    Letter from Mr. Lowe.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 2, 2023

 

VINCERX PHARMA, INC.
By:  

/s/ Raquel E. Izumi

  Raquel E. Izumi
  President and Chief Operations Officer
EX-17.1

Exhibit 17.1

Ahmed Handy MD

Chairman of the Board of Directors and CEO

Vincerx Corporation

Dear Vincerx team

I am writing to tender my resignation from the Board of Directors of Vincerx Corporation (the “Company”), effective December 31, 2022.

My decision to resign from the Company’s board of directors is the result of assessing the company strategy, upon which our views differ. I do not have any disagreement with the Company’s auditors or financials.

Best regards,

Andrew McDonald

 

EX-17.2

Exhibit 17.2

Ahmed Handy MD

Chairman of the Board of Directors and CEO

Vincerx Corporation

Dear Vincerx team

I am writing to tender my resignation from the Board of Directors of Vincerx Corporation (the “Company”), effective December 31, 2022.

My decision to resign from the Company’s board of directors is the result of assessing the company strategy, upon which our views differ. I do not have any disagreement with the Company’s auditors or financials.

Best regards,

Chris Lowe